Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019.
GBD 2019 Stroke Collaborators
https://pubmed.ncbi.nlm.nih.gov/34487721/Actively Recruiting
Led by Beijing Tiantan Hospital · Updated on 2026-04-23
1192
Participants Needed
41
Research Sites
26 weeks
Total Duration
Researchers are evaluating the efficacy and safety of oral minocycline in patients who have experienced an acute spontaneous intracerebral hemorrhage within 48 hours of onset. This prospective, multicenter, randomized, double-blind, placebo-controlled Phase III trial aims to improve patient outcomes and explore the effects of minocycline on venous neuroinflammation in this condition. Participants will be randomly assigned to receive either minocycline or a matching placebo for 5 days alongside standard medical care. The minocycline group will take an initial dose of 200 mg immediately after randomization, followed by 100 mg every 12 hours for a total of 10 doses. Those with swallowing difficulties may receive the medication through a nasal feeding tube. The trial includes screening, treatment, and follow-up phases with visits scheduled at screening, 72 hours, 7 days, 90 days, and 180 days after randomization. During the study, participants will undergo assessments including neurological evaluations and imaging at specified time points. Researchers will measure outcomes such as the modified Rankin Scale score at 90 days, changes in neurological scores, inflammation markers, and stroke recurrence. Safety and efficacy will be monitored through these evaluations, with total participation lasting up to 180 days post-randomization.
CONDITIONS
Efficacy and Safety of Minocycline in Acute Spontaneous Intracerebral Hemorrhage
K
Kaijiang Kang, MD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Beijing Tiantan Hospital
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 5 days
Participants receive either Minocycline or placebo capsules twice daily for 5 days in addition to standard medical care.
Visits at 72±12 hours and 7±1 days after randomization
Duration - Up to 6 months after treatment
Participants are monitored for safety and efficacy outcomes, including neurological assessments and quality of life measures.
Visits at 90±7 days and 180±7 days after randomization
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
GBD 2019 Stroke Collaborators
https://pubmed.ncbi.nlm.nih.gov/34487721/Wen-Juan Wang, Jing-Jing Lu, Yong-Jun Wang...
https://pubmed.ncbi.nlm.nih.gov/22943144/Abdelrahman Y Fouda, Andrea S Newsome, Samantha Spellicy...
https://pubmed.ncbi.nlm.nih.gov/28887388/Charlotte Cordonnier, Andrew Demchuk, Wendy Ziai...
https://pubmed.ncbi.nlm.nih.gov/30319113/Yao Lu, Ling Guan, Meiyang Zhang...
https://pubmed.ncbi.nlm.nih.gov/40147820/Teddy Y Wu, Gagan Sharma, Daniel Strbian...
https://pubmed.ncbi.nlm.nih.gov/28275199/Oliver Flower, Martin Smith
https://pubmed.ncbi.nlm.nih.gov/21169826/Qingfeng Ma, Rui Li, Lijun Wang...
https://pubmed.ncbi.nlm.nih.gov/34838196/Na Li, Jiahuan Guo, Kaijiang Kang...
https://pubmed.ncbi.nlm.nih.gov/36180765/Richard L Kraus, Rodger Pasieczny, Karen Lariosa-Willingham...
https://pubmed.ncbi.nlm.nih.gov/16033424/Beijing Tiantan Hospital
Lead Sponsor